Seelos Therapeutics (SEEL) Competitors $0.35 0.00 (0.00%) (As of 12/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SEEL vs. BDRX, SRNE, NEXI, PKBO, BLPH, PRFX, TCBP, ONCSQ, TCON, and SMFLShould you be buying Seelos Therapeutics stock or one of its competitors? The main competitors of Seelos Therapeutics include Biodexa Pharmaceuticals (BDRX), Sorrento Therapeutics (SRNE), NexImmune (NEXI), Peak Bio (PKBO), Bellerophon Therapeutics (BLPH), PainReform (PRFX), TC Biopharm (TCBP), OncoSec Medical (ONCSQ), TRACON Pharmaceuticals (TCON), and Smart for Life (SMFL). These companies are all part of the "pharmaceutical products" industry. Seelos Therapeutics vs. Biodexa Pharmaceuticals Sorrento Therapeutics NexImmune Peak Bio Bellerophon Therapeutics PainReform TC Biopharm OncoSec Medical TRACON Pharmaceuticals Smart for Life Biodexa Pharmaceuticals (NASDAQ:BDRX) and Seelos Therapeutics (NASDAQ:SEEL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, community ranking, media sentiment and dividends. Does the media refer more to BDRX or SEEL? In the previous week, Biodexa Pharmaceuticals had 1 more articles in the media than Seelos Therapeutics. MarketBeat recorded 1 mentions for Biodexa Pharmaceuticals and 0 mentions for Seelos Therapeutics. Biodexa Pharmaceuticals' average media sentiment score of 0.00 equaled Seelos Therapeutics'average media sentiment score. Company Overall Sentiment Biodexa Pharmaceuticals Neutral Seelos Therapeutics Neutral Do insiders & institutionals believe in BDRX or SEEL? 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 23.4% of Seelos Therapeutics shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Comparatively, 1.1% of Seelos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is BDRX or SEEL more profitable? Seelos Therapeutics has a net margin of 203.13% compared to Biodexa Pharmaceuticals' net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Biodexa PharmaceuticalsN/A N/A N/A Seelos Therapeutics 203.13%N/A -431.47% Which has more risk and volatility, BDRX or SEEL? Biodexa Pharmaceuticals has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, Seelos Therapeutics has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500. Which has better earnings and valuation, BDRX or SEEL? Biodexa Pharmaceuticals has higher earnings, but lower revenue than Seelos Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiodexa Pharmaceuticals$470K1.45-$7.66MN/AN/ASeelos Therapeutics$2.20M0.06-$37.88MN/AN/A Does the MarketBeat Community prefer BDRX or SEEL? Seelos Therapeutics received 70 more outperform votes than Biodexa Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Biodexa Pharmaceuticals an outperform vote while only 66.36% of users gave Seelos Therapeutics an outperform vote. CompanyUnderperformOutperformBiodexa PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesSeelos TherapeuticsOutperform Votes7166.36% Underperform Votes3633.64% Do analysts rate BDRX or SEEL? Biodexa Pharmaceuticals currently has a consensus price target of $200.00, indicating a potential upside of 3,421.13%. Given Biodexa Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Biodexa Pharmaceuticals is more favorable than Seelos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Seelos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryBiodexa Pharmaceuticals beats Seelos Therapeutics on 8 of the 14 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get Seelos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SEEL vs. The Competition Export to ExcelMetricSeelos TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$130,000.00$6.70B$5.22B$9.17BDividend YieldN/A8.02%5.73%4.01%P/E RatioN/A6.16102.3914.93Price / Sales0.06327.571,249.9388.11Price / CashN/A56.9841.6238.06Price / Book0.005.334.754.94Net Income-$37.88M$152.05M$119.41M$224.82M7 Day Performance7.69%7.22%2.52%1.84%1 Month Performance-49.26%4.06%2.02%9.09%1 Year Performance-99.81%28.05%31.93%28.53% Seelos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SEELSeelos TherapeuticsN/A$0.35flatN/A-99.9%$130,000.00$2.20M0.0020BDRXBiodexa Pharmaceuticals1.6723 of 5 stars$5.80+3.2%$200.00+3,348.3%N/A$690,000.00$83,000.000.0021Gap DownSRNESorrento TherapeuticsN/A$0.00-26.7%N/A-97.4%$606,000.00$62.84M0.00800Gap DownNEXINexImmuneN/A$0.410.0%N/A-92.5%$572,000.00N/A-0.026Gap DownPKBOPeak BioN/A$0.02-67.9%N/A-73.8%$520,000.00$370,000.00-0.143Gap DownHigh Trading VolumeBLPHBellerophon Therapeutics0.5065 of 5 stars$0.04-27.3%N/A+17.0%$489,000.00N/A-0.0520Analyst ForecastGap DownPRFXPainReform2.9467 of 5 stars$3.16+13.7%$8.00+153.2%-75.4%$458,000.00N/A-0.024Gap UpTCBPTC Biopharm0.5248 of 5 stars$0.56+0.6%N/A-99.1%$298,000.00$4.76M0.0041News CoveragePositive NewsGap DownONCSQOncoSec MedicalN/A$0.04+42,300.0%N/AN/A$253,000.00N/A0.0040Gap UpHigh Trading VolumeTCONTRACON Pharmaceuticals1.1606 of 5 stars$0.04-19.5%$60.00+171,328.6%-99.2%$119,000.00$12.05M0.0120Gap DownSMFLSmart for LifeN/A$0.01-72.9%N/A-99.9%$67,000.00$11.11M0.00110 Related Companies and Tools Related Companies BDRX Competitors SRNE Competitors NEXI Competitors PKBO Competitors BLPH Competitors PRFX Competitors TCBP Competitors ONCSQ Competitors TCON Competitors SMFL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SEEL) was last updated on 12/5/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredLock in this share price before 12/5When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying atten...Pacaso | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredWaveBot: The Automated Trading Tool for This Bull MarketThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seelos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seelos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SEEL Stock Alerts